Topics (74) View all

Skills (41)

Research experience

  • Teaching: endocrinology and medical decision making
  • Teaching: Clinical skills
  • Nov 2011–
    present
    Research: CICERO studies
    Ruhr-Universität Bochum · Medical Hospital I and Neurological Hospital, Bergmannsheil University Hospitals · Ruhr-Universität Bochum
    Germany · Bochum, NRW
  • Jul 2010–
    present
    Research: NOMOTHETICOS trial
    Bergmannsheil University Hospitals · Medical Hospital I · Bergmannsheil University Hospitals
    Germany · Bochum, NRW
    pituitary, thyroid, feedback, set-point
  • Jan 2008–
    present
    Research: Ruhr-Universität Bochum
    Ruhr-Universität Bochum
    Germany · Bochum
  • May 2007–
    present
    Research: AQUA FONTIS trials network
    Bergmannsheil University Hospitals · Medical Hospital I · Bergmannsheil University Hospitals
    Germany · Bochum, NRW
    NTIS, non-thyroidal illness syndrome, euthyroid sick syndrome
  • Jan 2006–
    present
    Research: Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil
    Bergmannsheil University Hospitals · Medical Hospital I · Lab XU44
    Germany · Bochum
  • Sep 2005–
    present
    Research: Endocrinology and Diabetes
    Ruhr University of Bochum · Bergmannsheil University Hospitals · Ruhr University of Bochum
    Germany · Bochum, NRW
  • Oct 2002–
    Aug 2005
    Research: Endocrinology and Diabetes
    Universität Ulm · Abteilung für Innere Medizin I · Universitätsklinikum Ulm
    Germany · Ulm, BW
  • Jan 2001–
    Sep 2002
    Research: Ludwig-Maximilians-Universität München
    Ludwig-Maximilians-Universität München · Institute of Medical Psychology (IMP)
    Germany · München
  • Sep 1995–
    Sep 2002
    Research: Endocrine Research
    University of Munich · Klinikum der LMU München · University of Munich
    Munich, BY
  • Apr 1995–
    Jan 2002
    Research: SPINA I study
    University of Munich · Klinikum der LMU München · University of Munich
    Munich, BY
    SPINA Thyr
  • Dec 1994–
    Aug 2002
    Research: Mathematical Modelling of Thyrotropic Feedback Control
    Ludwig-Maximilians-Universität München · Medical Downtown Hospital · Ludwig-Maximilians-Universität München
    Munich, BY
    SimThyr, SPINA Thyr

Education

  • Jul 2005
    Medizindidaktische Qualifikation I des Landes Baden-Württemberg
    Germany · Tübingen, BW
  • Jul 2005
    Seggau Castle
    Summer School 'Control Theory with Modeling Applications to Physiology and Medicine'
    Austria · Graz
  • Jul 1992
    Technische Universitat Munchen
    Techical and biological cybernetics
    Germany · München, BY
  • Nov 1987–
    Nov 1994
    Ludwig-Maximilian University of Munich
    Medicine · M.D.
    Germany · München, Bavaria

Awards & achievements

  • Jan 2011
    Award: Poster Prize of the North-Rhine-Westphalian Society for Endocrinology and Diabetology
  • Jan 2009
    Award: Poster Prize of the North-Rhine-Westphalian Society for Endocrinology and Diabetology
  • Apr 2002
    Award: Best paper award of the Symposium "Systems Science in Medicine" at the Sixteenth European Meeting on Cybernetics and Systems Research
  • Dec 1999
    Scholarship: Scholarship of the Democh-Maurmeier-Stipendienstiftung

Other

  • Languages
    German, English, Italian, Russian
  • Scientific Memberships
    European Association for the Study of Diabetes (EASD), European Society for Mathematical and Theoretical Biology, Deutsche Gesellschaft für Endokrinologie, Deutsche Gesellschaft für Innere Medizin, Nordrhein-Westfälische Gesellschaft für Endokrinologie und Diabetologie, Deutsche Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS), Gesellschaft für Medizinische Ausbildung (GMA), European Society of Endocrinology, Gesellschaft für Kybernetik, Tudmonda Asocio pri Kibernetiko, Informadiko kaj Sistemiko (TAKIS), Internationaler Wissenschaftlerkreis (ISK) der Internationalen Akademie der Wissenschaften (AIS) San Marino

Questions and Answers (71) View all

Publications (33) View all

  • Source
    Article: Normal values for longitudinal function of the right ventricle in healthy women >70 years of age.
    Alfried Germing, Michael Gotzmann, Ricarda Rausse, Turgut Brodherr, Stephan Holt, Michael Lindstaedt, Johannes Dietrich, Ulrich Ranft, Ursula Krämer, Andreas Mügge
    [show abstract] [hide abstract]
    ABSTRACT: The application of tricuspid annular plane systolic excursion (TAPSE) as an additional echocardiographic tool to analyse right ventricular (RV) systolic function has been recently established and two-dimensional-guided M-mode measurements of systolic long axis function of the RV are simple, repeatable, and highly reproducible. However, rare data are available on normal values. We aimed to analyse normal values in healthy women >70 years of age. In a cross-sectional survey, we investigated a cohort of randomly selected, non-hospitalized women >70 years of age. History of myocardial infarction, valvular heart disease, and diastolic dysfunction were exclusion criteria. In order to rule out left ventricular or RV dysfunction, a normal left ventricular ejection fraction and normal values of B-type natriuretic peptide (BNP) were necessary prior to study inclusion. A detailed echocardiographic examination was performed. A total of 80 participants were included (mean age 75 +/- 2.6 years). Mean left ventricular ejection fraction was 63.8 +/- 5.7%. Tissue Doppler derived mean E/E' ratio was 10 +/- 2.3. Mean right atrial diameter was 31.3 +/- 4.7 mm. Mean values for RV outflow tract and RV dimension were 27.3 +/- 3.6 and 28.8 +/- 3.7 mm, respectively. Mean TAPSE was 23.7 +/- 3.5 mm. Mean value of BNP was normal (42.5 +/- 35.7 pg/mL). In women >70 years of age without heart failure, structural heart disease, and neurohormonal activation, normal TAPSE values are approximately 24 mm.
    European Heart Journal – Cardiovascular Imaging 04/2010; 11(8):725-8. · 2.32 Impact Factor
  • Source
    Article: The parathyroid as a target for radiation damage.
    Bernhard O Boehm, Silke Rosinger, David Belyi, Johannes W Dietrich
    New England Journal of Medicine 08/2011; 365(7):676-8. · 53.30 Impact Factor
  • Article: Protection from diabetes development by single-chain antibody-mediated delivery of a NF-κB inhibitor specifically to β-cells in vivo.
    Sandra Ueberberg, Timo Deutschbein, Harald H Klein, Johannes W Dietrich, Sara Akinturk, Nora Prochnow, Ralph Schirrmacher, Stephan Schneider
    [show abstract] [hide abstract]
    ABSTRACT: Recently, we reported the generation of single-chain antibodies (SCAs) highly specific for rodent and human β-cells. Our current report describes the generation of a fusion protein of one of these SCAs (SCA B1) with a NF-κB essential modifier (NEMO)-binding domain (NBD) peptide, thereby creating a selective inhibitor of NF-κB activation in β-cells. The SCA B1-NBD fusion protein was cloned in the pIRES-EGFP, expressed in bacteria, and purified by metal affinity chromatography; the newly generated complex was then administered intravenously to rodents and evaluated for its ability to protect β-cells against cytokines in vitro and diabetogenic agents in vivo. First, it was shown clearly that our SCA B1-NBD fusion protein binds highly selective to CD rat β-cells in vivo. Second, we observed that SCA B1-mediated in vivo delivery of the NBD peptide completely blocked IL-1β + IFNγ- and TNFα + IFNγ-mediated induction of NF-κB as well as islet dysfunction in culture. Finally, repeated intravenous injection of SCA B1-NBD prior to multiple low-dose administration of streptozotocin in CD mice not only induced a striking resistance to diabetes development but also preserved β-cell mass. In conclusion, our data show for the first time that a SCA B1-NBD fusion peptide reliably protects β-cells against cytokines in vitro and allows protection from diabetes development in CD mice in vivo.
    AJP Endocrinology and Metabolism 04/2011; 301(1):E83-90. · 4.75 Impact Factor
  • Source
    Conference Proceeding: Amiodarone and radiocontrast agents correlate differently with the pattern of NTIS.
    A. Urban, A. Jeyabalan, A. Ackermann, Y. Kanthasamy, T. Tharmalingam, A. Stachon, R. Köditz, R. Gärtner, E. Conrad-Opel, H.H. Klein, S. Hering, J. W. Dietrich
    ITC 2010, Paris; 01/2010
  • Source
    Article: Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo.
    Sandra Ueberberg, Juris J Meier, Carmen Waengler, Wolfgang Schechinger, Johannes W Dietrich, Andrea Tannapfel, Inge Schmitz, Ralf Schirrmacher, Manfred Köller, Harald H Klein, Stephan Schneider
    [show abstract] [hide abstract]
    ABSTRACT: Noninvasive determination of pancreatic beta-cell mass in vivo has been hampered by the lack of suitable beta-cell-specific imaging agents. This report outlines an approach for the development of novel ligands homing selectively to islet cells in vivo. To generate agents specifically binding to pancreatic islets, a phage library was screened for single-chain antibodies (SCAs) on rat islets using two different approaches. 1) The library was injected into rats in vivo, and islets were isolated after a circulation time of 5 min. 2) Pancreatic islets were directly isolated, and the library was panned in the islets in vitro. Subsequently, the identified SCAs were extensively characterized in vitro and in vivo. We report the generation of SCAs that bind highly selective to either beta- or alpha-cells. These SCAs are internalized by target cells, disappear rapidly from the vasculature, and exert no toxicity in vivo. Specific binding to beta- or alpha-cells was detected in cell lines in vitro, in rats in vivo, and in human tissue in situ. Electron microscopy demonstrated binding of SCAs to the endoplasmatic reticulum and the secretory granules. Finally, in a biodistribution study the labeling intensity derived from [(125)I]-labeled SCAs after intravenous administration in rats strongly predicted the beta-cell mass and was inversely related to the glucose excursions during an intraperitoneal glucose tolerance test. Our data provide strong evidence that the presented SCAs are highly specific for pancreatic beta-cells and enable imaging and quantification in vivo.
    Diabetes 08/2009; 58(10):2324-34. · 8.29 Impact Factor

Following (103) See all

Followers (161) See all

Browse more researchers